{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:51:19Z","timestamp":1792792279886,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773794"],"award-info":[{"award-number":["81773794"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974507"],"award-info":[{"award-number":["81974507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004307","name":"Distinguished Middle-Aged and Young Scientist Encourage and Reward Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020JQ31"],"award-info":[{"award-number":["ZR2020JQ31"]}],"id":[{"id":"10.13039\/501100004307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI027690"],"award-info":[{"award-number":["R01AI027690"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ts20190902"],"award-info":[{"award-number":["ts20190902"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["GXL20200015001"],"award-info":[{"award-number":["GXL20200015001"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV-1 reverse transcriptase is one of the most attractive targets for the treatment of AIDS. However, the rapid emergence of drug-resistant strains and unsatisfactory drug-like properties seriously limit the clinical application of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Here we show that a series of piperazine sulfonyl-bearing diarylpyrimidine-based NNRTIs were designed to improve the potency against wild-type and NNRTI-resistant strains by enhancing backbone-binding interactions. Among them, compound <jats:bold>18b1<\/jats:bold> demonstrates single-digit nanomolar potency against the wild-type and five mutant HIV-1 strains, which is significantly better than the approved drug etravirine. The co-crystal structure analysis and molecular dynamics simulation studies were conducted to explain the broad-spectrum inhibitory activity of <jats:bold>18b1<\/jats:bold> against reverse transcriptase variants. Besides, compound <jats:bold>18b1<\/jats:bold> demonstrates improved water solubility, cytochrome P450 liability, and other pharmacokinetic properties compared to the currently approved diarylpyrimidine (DAPY) NNRTIs. Therefore, we consider compound <jats:bold>18b1<\/jats:bold> a potential lead compound worthy of further study.<\/jats:p>","DOI":"10.1038\/s42004-023-00888-4","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T13:02:29Z","timestamp":1682773349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-2513","authenticated-orcid":false,"given":"Xiangyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Rumrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0980-9266","authenticated-orcid":false,"given":"David","family":"Pople","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-6325","authenticated-orcid":false,"given":"Waleed A.","family":"Zalloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-953X","authenticated-orcid":false,"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lide","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc X.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-6026","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","volume":"62","author":"V Namasivayam","year":"2019","unstructured":"Namasivayam, V. et al. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J. Med. Chem. 62, 4851\u20134883 (2019).","journal-title":"J. Med. Chem."},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1021\/ja4018418","volume":"135","author":"G Bec","year":"2013","unstructured":"Bec, G. et al. Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors. J. Am. Chem. Soc. 135, 9743\u20139752 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"e36340","DOI":"10.7554\/eLife.36340","volume":"7","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d] pyrimidine non-nucleoside inhibitors. Elife 7, e36340 (2018).","journal-title":"Elife"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1021\/acs.jmedchem.1c00268","volume":"64","author":"DW Kang","year":"2021","unstructured":"Kang, D. W. et al. 2,4,5-trisubstituted pyrimidines as potent HIV-1 NNRTIs: rational design, synthesis, activity evaluation, and crystallographic studies. J. Med. Chem. 64, 4239\u20134256 (2021).","journal-title":"J. Med. Chem."},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/med.21544","volume":"39","author":"L Battini","year":"2019","unstructured":"Battini, L. & Bollini, M. Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors. Med. Res. Rev. 39, 1235\u20131273 (2019).","journal-title":"Med. Res. Rev."},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","volume":"10","author":"D Kang","year":"2019","unstructured":"Kang, D. et al. Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharm. Sin. B. 10, 878\u2013894 (2019).","journal-title":"Acta Pharm. Sin. B."},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"13604","DOI":"10.1021\/acs.jmedchem.1c00987","volume":"64","author":"B Huang","year":"2021","unstructured":"Huang, B. et al. Structure-based design and discovery of pyridyl-bearing fused bicyclic HIV-1 inhibitors: synthesis, biological characterization, and molecular modeling studies. J. Med. Chem. 64, 13604\u201313621 (2021).","journal-title":"J. Med. Chem."},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","volume":"121","author":"ME Cilento","year":"2021","unstructured":"Cilento, M. E., Kirby, K. A. & Sarafianos, S. G. Avoiding drug resistance in HIV reverse transcriptase. Chem. Rev. 121, 3271\u20133296 (2021).","journal-title":"Chem. Rev."},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMra1004180","volume":"365","author":"MA Wainberg","year":"2011","unstructured":"Wainberg, M. A., Zaharatos, G. J. & Brenner, B. G. Mechanisms of disease development of antiretroviral drug resistance. N. Engl. J. Med. 365, 637\u2013646 (2011).","journal-title":"N. Engl. J. Med."},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer, C. & Pozniak, A. HIV drug resistance\u2014an emerging threat to epidemic control. N. Engl. J. Med. 377, 1605\u20131607 (2017).","journal-title":"N. Engl. J. Med."},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang, Y., De Clercq, E. & Li, G. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin. Drug Metab. Toxicol. 15, 813\u2013829 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"888_CR12","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","volume":"63","author":"D Kang","year":"2020","unstructured":"Kang, D. et al. Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties. J. Med. Chem. 63, 4837\u20134848 (2020).","journal-title":"J. Med. Chem."},{"key":"888_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/13543776.2016.1113256","volume":"26","author":"BS Huang","year":"2016","unstructured":"Huang, B. S. et al. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin. Ther. Pat. 26, 281\u2013289 (2016).","journal-title":"Expert Opin. Ther. Pat."},{"key":"888_CR14","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1021\/jm049439i","volume":"48","author":"Y Frenkel","year":"2005","unstructured":"Frenkel, Y. et al. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 48, 1974\u20131983 (2005).","journal-title":"J. Med. Chem."},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/acschembio.5b00806","volume":"11","author":"C McLaughlin","year":"2016","unstructured":"McLaughlin, C. et al. Stable colloidal drug aggregates catch and release active enzymes. ACS Chem. Biol. 11, 992\u20131000 (2016).","journal-title":"ACS Chem. Biol."},{"key":"888_CR16","doi-asserted-by":"crossref","unstructured":"Ganesh, A. N. et al. Colloidal drug aggregate stability in high serum conditions and pharmacokinetic consequence. ACS Chem. Biol. 14,751\u2013757 (2019).","DOI":"10.1021\/acschembio.9b00032"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17425255.2019.1604685","volume":"15","author":"Y Gong","year":"2019","unstructured":"Gong, Y. et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin. Drug Metab. Toxicol. 15, 417\u2013427 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/med.20241","volume":"33","author":"P Zhan","year":"2013","unstructured":"Zhan, P. et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design. Med. Res. Rev. 33, E1\u2013E72 (2013).","journal-title":"Med. Res. Rev."},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","volume":"31","author":"J Du","year":"2020","unstructured":"Du, J. et al. New techniques and strategies in drug discovery. Chin. Chem. Lett. 31, 1695\u20131708 (2020).","journal-title":"Chin. Chem. Lett."},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/med.21581","volume":"39","author":"XY Jiang","year":"2019","unstructured":"Jiang, X. Y. et al. Molecular design opportunities presented by solvent-exposed regions of target proteins. Med. Res. Rev. 39, 2194\u20132238 (2019).","journal-title":"Med. Res. Rev."},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"62","author":"BS Huang","year":"2019","unstructured":"Huang, B. S. et al. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J. Med. Chem. 62, 2083\u20132098 (2019).","journal-title":"J. Med. Chem."},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"113204","DOI":"10.1016\/j.ejmech.2021.113204","volume":"214","author":"YY Sun","year":"2021","unstructured":"Sun, Y. Y. et al. Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. Eur. J. Med. Chem. 214, 113204 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"113051","DOI":"10.1016\/j.ejmech.2020.113051","volume":"213","author":"XY Jiang","year":"2021","unstructured":"Jiang, X. Y. et al. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp(3) values and favorable drug-like properties. Eur. J. Med. Chem. 213, 113051 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2174\/092986709789178019","volume":"16","author":"P Zhan","year":"2009","unstructured":"Zhan, P., Liu, X. Y., Li, Z. Y., Pannecouque, C. & De Clercq, E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem. 16, 3903\u20133917 (2009).","journal-title":"Curr. Med. Chem."},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13543776.2017.1262349","volume":"27","author":"BS Huang","year":"2017","unstructured":"Huang, B. S. et al. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Expert Opin. Ther. Pat. 27, 9\u201315 (2017).","journal-title":"Expert Opin. Ther. Pat."},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.bmcl.2010.03.006","volume":"20","author":"CS Leung","year":"2010","unstructured":"Leung, C. S. et al. Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. Bioorg. Med. Chem. Lett. 20, 2485\u20132488 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"888_CR27","first-page":"815","volume":"20","author":"YN Song","year":"2013","unstructured":"Song, Y. N. et al. Multivalent agents: a novel concept and preliminary practice in anti-HIV drug discovery. Curr. Med. Chem. 20, 815\u2013832 (2013).","journal-title":"Curr. Med. Chem."},{"key":"888_CR28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2174\/138955709788681618","volume":"9","author":"P Zhan","year":"2009","unstructured":"Zhan, P., Li, Z. Y., Liu, X. Y. & De Clercq, E. Sulfanyltriazole\/tetrazoles: a promising class of HIV-1 NNRTIs. Mini Rev. Med. Chem. 9, 1014\u20131023 (2009).","journal-title":"Mini Rev. Med. Chem."},{"key":"888_CR29","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1021\/jm1002233","volume":"53","author":"EB Lansdon","year":"2010","unstructured":"Lansdon, E. B. et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem. 53, 4295\u20134299 (2010).","journal-title":"J. Med. Chem."},{"key":"888_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ejmech.2017.02.047","volume":"130","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. Eur. J. Med. Chem. 130, 209\u2013222 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"888_CR31","doi-asserted-by":"publisher","first-page":"103248","DOI":"10.1016\/j.bioorg.2019.103248","volume":"94","author":"JY Bao","year":"2020","unstructured":"Bao, J. Y. et al. Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors. Bioorg. Chem. 94, 103248 (2020).","journal-title":"Bioorg. Chem."},{"key":"888_CR32","doi-asserted-by":"publisher","first-page":"112162","DOI":"10.1016\/j.ejmech.2020.112162","volume":"191","author":"LI Pilkington","year":"2020","unstructured":"Pilkington, L. I. et al. Development, synthesis and biological investigation of a novel class of potent PC-PLC inhibitors. Eur. J. Med. Chem. 191, 112162 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"888_CR33","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","volume":"59","author":"DW Kang","year":"2016","unstructured":"Kang, D. W. et al. Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J. Med. Chem. 59, 7991\u20138007 (2016).","journal-title":"J. Med. Chem."},{"key":"888_CR34","doi-asserted-by":"publisher","first-page":"28961","DOI":"10.1039\/C9RA05869A","volume":"9","author":"XY Jiang","year":"2019","unstructured":"Jiang, X. Y. et al. Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. Rsc Adv. 9, 28961\u201328986 (2019).","journal-title":"Rsc Adv."},{"key":"888_CR35","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1021\/jm00395a010","volume":"30","author":"MJ Brienne","year":"1987","unstructured":"Brienne, M. J. et al. New antifilarial agents .1. Epoxy sulfonamides and ethynesulfonamides. J. Med. Chem. 30, 2232\u20132239 (1987).","journal-title":"J. Med. Chem."},{"key":"888_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nprot.2007.517","volume":"3","author":"C Pannecouque","year":"2008","unstructured":"Pannecouque, C., Daelemans, D. & De Clercq, E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat. Protoc. 3, 427\u2013434 (2008).","journal-title":"Nat. Protoc."},{"key":"888_CR37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.0711209105","volume":"105","author":"K Das","year":"2008","unstructured":"Das, K. et al. High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA 105, 1466\u20131471 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"888_CR38","doi-asserted-by":"publisher","first-page":"D437","DOI":"10.1093\/nar\/gkaa1038","volume":"49","author":"SK Burley","year":"2021","unstructured":"Burley, S. K. et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 49, D437\u2013D451 (2021).","journal-title":"Nucleic Acids Res."},{"key":"888_CR39","doi-asserted-by":"publisher","first-page":"41576","DOI":"10.1074\/jbc.R112.418574","volume":"287","author":"S Horowitz","year":"2012","unstructured":"Horowitz, S. & Trievel, R. C. Carbon-oxygen hydrogen bonding in biological structure and function. J. Biol. Chem. 287, 41576\u201341582 (2012).","journal-title":"J. Biol. Chem."},{"key":"888_CR40","doi-asserted-by":"publisher","first-page":"15301","DOI":"10.1073\/pnas.1208341109","volume":"109","author":"JC Chen","year":"2012","unstructured":"Chen, J. C., Hanson, B. L., Fisher, S. Z., Langan, P. & Kovalevsky, A. Y. Direct observation of hydrogen atom dynamics and interactions by ultrahigh resolution neutron protein crystallography. Proc. Natl Acad. Sci. USA 109, 15301\u201315306 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"888_CR41","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1021\/jm0492249","volume":"48","author":"AC Pierce","year":"2005","unstructured":"Pierce, A. C. et al. CH\u2026O and CH\u2026N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor. J. Med. Chem. 48, 1278\u20131281 (2005).","journal-title":"J. Med. Chem."},{"key":"888_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1021\/acs.jpca.9b10726","volume":"124","author":"AL Webber","year":"2020","unstructured":"Webber, A. L. et al. Weak intermolecular CH\u2026N hydrogen bonding: determination of (13)CH-(15)N hydrogen-bond mediated J couplings by solid-state NMR spectroscopy and first-principles calculations. J. Phys. Chem. A 124, 560\u2013572 (2020).","journal-title":"J. Phys. Chem. A"},{"key":"888_CR43","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller","year":"2012","unstructured":"Miller, B. R. et al. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314\u20133321 (2012).","journal-title":"J. Chem. Theory Comput."},{"key":"888_CR44","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1021\/acsmedchemlett.9b00409","volume":"10","author":"B Cox","year":"2019","unstructured":"Cox, B., Booker-Milburn, K. I., Elliot, L. D., Robertson-Ralph, M. & Zdorichenko, V. Escaping from Flatland: [2+2] photocycloaddition; conformationally constrained sp(3)-rich Scaffolds for lead generation. ACS Med. Chem. Lett. 10, 1512\u20131517 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"888_CR45","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","volume":"25","author":"WX Wei","year":"2020","unstructured":"Wei, W. X. et al. Fsp(3): a new parameter for drug-likeness. Drug Discov. Today 25, 1839\u20131845 (2020).","journal-title":"Drug Discov. Today"},{"key":"888_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2174\/1389203719666190527080832","volume":"20","author":"J Polanski","year":"2019","unstructured":"Polanski, J. et al. Ligand potency, efficiency and drug-likeness: a story of intuition, misinterpretation and serendipity. Curr. Protein Pept. Sci. 20, 1069\u20131076 (2019).","journal-title":"Curr. Protein Pept. Sci."},{"key":"888_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/17460441.2017.1365056","volume":"12","author":"MM Cavalluzzi","year":"2017","unstructured":"Cavalluzzi, M. M. et al. Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. Expert Opin. Drug Dis. 12, 1087\u20131104 (2017).","journal-title":"Expert Opin. Drug Dis."},{"key":"888_CR48","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/17460441.2.4.469","volume":"2","author":"C Abad-Zapatero","year":"2007","unstructured":"Abad-Zapatero, C. Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discov. 2, 469\u2013488 (2007).","journal-title":"Expert Opin. Drug Discov."},{"key":"888_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrd4163","volume":"13","author":"AL Hopkins","year":"2014","unstructured":"Hopkins, A. L. et al. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105\u2013121 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"888_CR50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0213-005X(09)73216-1","volume":"27","author":"VE Perez","year":"2009","unstructured":"Perez, V. E., Sanchez-Parra, C. & Serrano Villar, S. Etravirine drug interactions. Enferm. Infecc. Microbiol. Clin. 27, 27\u201331 (2009).","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"888_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","volume":"16","author":"I Usach","year":"2013","unstructured":"Usach, I., Melis, V. & Peris, J. E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. Aids Soc. 16, 1\u201314 (2013).","journal-title":"J. Int. Aids Soc."}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-023-00888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-023-00888-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-023-00888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T14:05:29Z","timestamp":1682777129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-023-00888-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1038\/s42004-023-00888-4","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}